SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat year-over-year at $14.6MM.
The company announced full-year 2018 guidance in the range of $135.0MM to $139.0MM, for potentially 5% growth vs. 2017.
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat...
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat year-over-year at $14.6MM.
The company announced full-year 2018 guidance in the range of $135.0MM to $139.0MM, for potentially 5% growth vs. 2017.
Copy to clipboard 
